Welcome to our dedicated page for Veru news (Ticker: VERU), a resource for investors and traders seeking the latest updates and insights on Veru stock.
Veru Inc. (NASDAQ: VERU) is a late clinical-stage biopharmaceutical company advancing innovative therapies for cardiometabolic diseases, oncology, acute respiratory distress syndrome (ARDS), and sexual health. This page provides investors and stakeholders with timely updates on clinical trial progress, regulatory milestones, and strategic initiatives.
Access the latest Veru news, including press releases on drug development programs like enobosarm for muscle preservation during weight loss and sabizabulin for inflammatory conditions. Stay informed about earnings updates, partnership announcements, and scientific advancements across Veru's diversified pipeline.
All content is sourced directly from company communications and vetted financial news outlets. Bookmark this page for streamlined access to critical updates affecting Veru investment analysis and market positioning.
Veru Inc. (NASDAQ: VERU) has adjourned its 2024 Annual Shareholders Meeting, initially scheduled for June 18, 2024, to June 27, 2024, due to a lack of quorum. The meeting was convened without any business conducted as only 49.6% of shareholders' proxies were submitted, short of the required majority. Shareholders who previously voted do not need to take any further action; their votes will be counted in the rescheduled meeting unless revoked. The record date remains April 29, 2024. Shareholders are encouraged to vote to avoid additional costs.
Veru, a late clinical-stage biopharmaceutical company listed on NASDAQ under the symbol VERU, reminds shareholders to vote ahead of its 2024 Annual Meeting of Shareholders. The meeting is set for June 18, 2024, at 9:00 AM ET. Shareholders should submit their votes before the proxy voting deadline, which is also on June 18, 2024, at 9:00 AM ET. Voting can be done online or via telephone based on instructions in the Form of Proxy or Voting Instruction Form. Detailed materials are available on the company’s website.
Veru, a clinical stage biopharmaceutical company (NASDAQ: VERU), will present at the American Diabetes Association's 84th Scientific Sessions from June 21-24, 2024, in Orlando, Florida.
The company will showcase two presentations on June 22, 2024:
1. A pooled safety analysis of Enobosarm from Phase 2 and Phase 3 placebo-controlled clinical trials.
2. A meta-analysis of body composition from three randomized clinical trials, highlighting Enobosarm’s ability to preserve muscle while reducing fat.
Both presentations are scheduled from 12:30 PM to 01:30 PM EDT at the West Concourse A4-B2.
Veru (NASDAQ: VERU), a biopharmaceutical company, announced that its CEO, Mitchell Steiner, M.D., will present at the Jefferies Global Healthcare Conference on June 5, 2024, from 11:00 am to 11:25 am ET. The presentation will focus on the Phase 2b clinical program of enobosarm. Enobosarm aims to augment fat loss and prevent muscle loss when combined with GLP-1 drugs for weight loss. A live webcast of the presentation will be available on Veru's website, with an archived version accessible post-event.
Veru (NASDAQ: VERU) has announced the appointment of Dr. Steven B. Heymsfield as the Principal Investigator for its Phase 2b clinical trial of enobosarm, aimed at preserving muscle while enhancing fat loss in patients using GLP-1 RAs for weight loss.
Dr. Heymsfield is a renowned expert in body composition and obesity, with extensive experience in clinical research and over 600 peer-reviewed publications. The trial seeks to address the issue of muscle loss in weight loss treatments. Veru anticipates enrolling the trial quickly and expects data by year-end.
Veru, a biopharmaceutical company specializing in innovative medicine for oncology and viral-induced acute respiratory distress syndrome, will see its CEO, Dr. Mitchell Steiner, present a keynote at Biomed Israel 2024. The event, taking place May 21-23 in Tel Aviv, Israel, focuses on life science and technology advancements. Dr. Steiner's presentation, scheduled for May 22, will discuss the effects of GLP-1 receptor agonists on muscle loss and weight management, particularly in older sarcopenic obese patients. The session aims to explore how preserving muscle mass can enhance the effectiveness of weight loss drugs.
Veru Inc. reported fiscal 2024 second quarter financial results and provided updates on its Enobosarm high-quality weight loss clinical program. The Phase 2b clinical study of enobosarm in combination with semaglutide is actively enrolling. The company has formed a high-quality weight loss Scientific Advisory Board with five medical experts and will present at upcoming medical conferences. Veru Inc. aims to develop innovative medicines for weight loss, oncology, and respiratory distress syndrome.
Veru Inc. (NASDAQ: VERU) will present at the GLP-1 Based Therapeutics Summit in Philadelphia, discussing Enobosarm, a drug to avoid muscle loss and enhance weight loss quality. The presentation aims to address muscle loss issues in weight management and the potential benefits of combining Enobosarm with a GLP-1 RA. The event is scheduled for May 15-16, 2024.
Veru Inc. (NASDAQ: VERU) will host a conference call and webcast on May 8, 2024, to discuss its fiscal 2024 second quarter financial results and provide a business update. The company focuses on developing innovative medicines for weight loss, oncology, and respiratory distress syndrome.
Veru Inc. (NASDAQ: VERU) has enrolled the first patients in a Phase 2b clinical trial of enobosarm and semaglutide combination for high-quality weight loss. The study aims to preserve muscle mass during weight loss therapy, with topline data expected in the fourth quarter of 2024.
FAQ
What is the current stock price of Veru (VERU)?
What is the market cap of Veru (VERU)?
